Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.

ABSTRACT: Successes of immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T cell therapy in curing patients with otherwise lethal cancers have validated immunotherapy as a treatment for cancer and have inspired excitement for its broader potential. Most promising is the ability of each approach to eliminate bulky and advanced-stage cancers and to achieve durable cures. Despite this success, to date only a subset of cancer patients and a limited number of cancer types respond to these therapies. A major goal now is to expand the types of cancer and number of patients who can be successfully treated. To this end a multitude of immunotherapies are being tested clinically in new combinations, and many new immunomodulatory antibodies and CARs are in development. A third major immunot

SUBMITTER: Lohmueller J 

PROVIDER: S-EPMC5600680 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature